High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study
Xia et al.
, High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic: a retrospective cohort study
, Aging, doi:10.18632/aging.203503
Retrospective 113 severe and critical patients in China with cardiac injury, 51 treated with high dose vitamin C, showing treatment associated with improvement of myocardial injury.
Xia et al., 7 Sep 2021, China, peer-reviewed, 5 authors.
AGING 2021, Vol. 13, No. 17
High-dose vitamin C ameliorates cardiac injury in COVID-19 pandemic:
a retrospective cohort study
Guozhi Xia1, Bowen Qin2, Chaoran Ma3, Yaowu Zhu4, Qiangsun Zheng1
Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi
National-Local Joint Engineering Research Center of Biodiagnostics and Biotherapy, The Second Affiliated
Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
Department of Nutritional Sciences, Pennsylvania State University, University Park, PA 16802, USA
Department of Laboratory Medicine, Tongji Hospital of Huazhong University of Science and Technology, Wuhan
430030, Hubei Province, China
Correspondence to: Guozhi Xia; email: firstname.lastname@example.org, https://orcid.org/0000-0002-6307-4563
Keywords: vitamin C, inflammation, cardiac injury, COVID-19
Received: March 11, 2021
Accepted: August 23, 2021
Published: September 9, 2021
Copyright: © 2021 Xia et al. This is an open access article distributed under the terms of the Creative Commons Attribution
License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original
author and source are credited.
Background: Cardiac injury is common and associated with poor clinical outcomes in COVID-19. Data are lacking
whether high-dose intravenous vitamin C (HIVC) could help to ameliorate myocardial injury in the pandemic.
Methods: The retrospective cohort study included consecutive severe and critically ill COVID-19 patients with
cardiac injury receiving symptomatic supportive treatments alone or together with HIVC. Troponin I and
inflammatory markers were collected at admission and day 21 during hospitalization from the electronic
Results: The patients (n = 113) were categorized into the ameliorated cardiac injury (ACI) group (n = 70) and the
non-ameliorated cardiac injury (NACI) group (n = 43). Overall, fifty-one (45.1%) patients were administered with
HIVC, the percentages of patients with HIVC were higher in the ACI group than those in the NACI group. Logistic
regression analysis revealed that HIVC was independently associated with the improvement of myocardial
injury. Further analysis showed that inflammatory markers levels significantly decreased at day 21 during
hospitalization in patients with HIVC therapy compared to those administered with symptomatic supportive
treatments alone. Meanwhile, similar results were also observed regarding changes in inflammatory markers
levels from baseline to day 21 during hospitalization in the patients treated with HIVC.
Conclusions: HIVC can ameliorate cardiac injury through alleviating hyperinflammation in severe and critically
ill patients with COVID-19.
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.